Tagged with M

India Indian pharma production is growing rapidly – boosted by the Modi government’s ‘Make in India’ campaign – and both Indian companies and multinationals implanted in the world’s second most populous nation are responding to the drastic need for quality, affordable generic medicines across the world. “When it comes to manufacturing…

Brazil Bruno Costa Gabriel, managing director of Janssen Brazil, provides insights into the transformative market approach successfully implemented by this leading company in Brazil and his main priorities to further leverage the great potential of Janssen’s innovation and impact an ever-increasing number of Brazilian patients.   You display a truly international…

Poland Sabina Sampławska, director, head of life sciences at KPMG Poland, discusses the challenge of pricing pressures and how their innovative services help companies manage this trend, as well as the need for data transparency in constructing correct strategies for clients. She also highlights the role KPMG is playing in bringing…

Bulgaria Kalin Tochev, country manager of IQVIA Bulgaria, discusses the main trends taking place in the Bulgarian pharmaceutical sector and highlights the end-to-end approach that IQVIA offers to its clients to help them successfully navigate a dynamic environment. Mr. Tochev, you have a quite unusual profile coming from different industries such…

Brazil Pius Hornstein, MSc, PhD, country chair Sanofi Brazil and general manager Pharma, shares his positive outlook on the Brazilian pharma market over the next few years and details Sanofi’s strategy in Brazil; a ‘must-win’ market for the company. Unsatisfied with being just the top-ranked multinational pharma company in Brazil, he…

Switzerland Marina Lugova, executive VP Business Development at API manufacturer Synbias Pharma, discusses why Switzerland was chosen as the company’s headquarters, Synbias’s internationalization strategy, and why it is the partner of choice.   We have chosen Switzerland for several reasons: a stable political and economic environment, the fact many Big Pharma…

Brazil Laurena de Almeida Magnoni, regional director for Latin America at Besins Healthcare, a pharmaceutical company specialized in the development and worldwide diffusion of innovative drugs and food supplements for men’s and women’s health, provides insights into the impressive growth of the Brazilian operations over the past six years, her recipe…

Canada Quebec’s Deputy Premier and Minister of Economy, Science and Innovation Dominique Anglade, who is also the Minister responsible for the Digital Strategy, shares the strategic significance of her portfolios to Quebec’s national development, the CAD 205 million Quebec is investing into the life sciences sectors over the next five years,…

Brazil Norberto Prestes, director of the Brazilian Pharmochemicals Manufacturers Association (ABIQUIFI), provides insights into the main dynamics that have been shaping Brazil’s pharmaceutical and API sectors over the past few years, while highlighting his main priorities to further strengthen the country’s pharma industry both inside and outside Brazil. What would you…

Merck Belén Garijo, global CEO of Merck Healthcare, speaking this month at the FT Global Pharmaceutical and Biotechnology Conference, ‘Thriving Amid Uncertainty’, in London, underlined the significance of Merck’s new deal with NHS England for its innovative new multiple sclerosis (MS) treatment, Mavenclad and how this deal stands as a new…

Japan Yuzo Toda, chairman of the Forum for Innovative Regenerative Medicine (FIRM) in Japan, discusses how the organization acts as a translational bridge between academia and industry, how the paradigm of regenerative medicine differs from that of traditional pharmaceuticals, and why Japan has taken the lead in this exciting new field.…

Japan Dr. Tatsuya Kondo is chief executive of Japan’s regulatory authority, the Pharmaceuticals and Medical Devices Agency (PMDA). Since taking the role in 2008, Dr. Kondo, a qualified neurosurgeon with wide-ranging experience in R&D activities, has been responsible for all the operations of PMDA, including relief for adverse health effects of…